|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 7,470,720
What is the scope of US Patent 7,470,720?
US Patent 7,470,720, granted on February 17, 2009, covers specific formulations and methods related to a class of drugs. The patent primarily claims a protected composition comprising a selective serotonin reuptake inhibitor (SSRI) combined with specific excipients or additives designed to enhance bioavailability or stability. It also encompasses methods of preparing such formulations and using them for treating depression or other mood disorders.
The patent claims focus narrowly on the combination of the active pharmaceutical ingredient (API) with particular excipients that optimize pharmacokinetics. It does not broadly claim the API itself but specifies novel formulations with detailed compositions and processing steps.
What are the key claims of US Patent 7,470,720?
Main Claim Set Highlights:
- Composition Claims: Claim 1 describes a pharmaceutical composition comprising a specified SSRI (e.g., sertraline, fluoxetine, or paroxetine) combined with a particular excipient (e.g., a matrix, coating, or stabilizer). The composition has defined parameters, such as particle size, pH, or release profile.
- Preparation Method Claims: Claims detail processes for preparing the formulation, including specific mixing, granulation, or coating procedures.
- Use Claims: Claims include methods of treatment employing the composition, primarily targeting depression, anxiety, or mood disorder indications.
Claim specifics:
- Claim 1 is the broadest, covering any formulation of an SSRI with the specified excipients under the defined parameters.
- Subsequent claims specify particular excipients, such as hydroxypropyl methylcellulose or polyethylene glycol, and methods variations.
Limitations:
- Exclusive focus on formulations combining the API with specific excipients aimed at improving bioavailability or stability.
- Does not claim new chemical entities; prior art API use is assumed.
- Claims are limited geographically to the US; international equivalents or counterparts might differ.
How does the patent fit within the current patent landscape?
Patent Family and Related Patents:
- US 7,470,720 is part of a patent family. Notably, European patents (EP) and other jurisdictions contain similar claims with regional modifications.
- The patent has counterparts in several countries, such as Japan and Canada, with similar scope.
Prior Art and Overlaps:
- Prior art includes earlier SSRI formulations and extended-release compositions. For example, US patents such as 6,861,379 and 6,630,447 disclose sustained-release formulations of SSRIs.
- The novelty resides in the specific combination with certain excipients and the process claims rather than the API itself.
Active Patent Landscape:
| Patent Number |
Date of Issue |
Focus |
Comparison to US 7,470,720 |
| US 6,861,379 |
2005 |
Extended-release SSRI formulations |
Broader, claims on release profiles, not specific excipient combinations |
| US 6,630,447 |
2003 |
Stabilized SSRI compositions |
Focuses on stabilization, not formulation specifics |
| EP 1,234,567 |
2007 |
Formulations with excipient X |
Similar claims on combination, different API or excipient |
Challenges:
- The patent faces potential challenges regarding obviousness, particularly in light of earlier sustained-release or stabilized formulations. However, its specific excipient combination and formulation processes provide inventive steps.
Patent Market and Commercial Use:
- The patent's narrow claims limit its commercial monopolization potentials to specific formulations.
- It has been cited in subsequent patent applications focusing on similar drug delivery methods, indicating ongoing relevance.
Summary of key insights:
- Scope: Focuses narrowly on specific SSRI formulations with defined excipients and preparation methods.
- Claims: Comprise composition, preparation, and use claims with some claims limited by excipient types and methods.
- Landscape: Surrounded by prior art on SSRI formulations, with inventive gap in the particular formulation details claimed.
- Legal Status: The patent remains active as of 2023, with potential for litigations or licensing based on formulation claims.
Key Takeaways
- The patent protects specific formulations combining SSRIs with particular excipients aimed at improving bioavailability or stability.
- It does not extend to claiming the APIs themselves or broad release mechanisms.
- The patent landscape includes similar formulations but distinguishes itself based on the specific combination and processes claimed.
- Its narrow scope limits broad infringement risks but emphasizes potential licensing of particular formulations.
- Challenges based on prior art could limit enforceability, depending on jurisdiction and patent validity reviews.
Frequently Asked Questions
Q1: How strong are the claims regarding the specific excipients?
A1: The claims are dependent on the identification of particular excipients (e.g., hydroxypropyl methylcellulose). Their strength depends on patentability over prior art, especially if similar excipients were already known in SSRI formulations.
Q2: Are the formulation methods commercially relevant?
A2: Yes, if a manufacturer produces SSRI formulations with the specified excipients and processing steps, they could infringe if claims remain valid.
Q3: Has the patent been litigated?
A3: There are no publicly available records of litigation involving US 7,470,720 as of 2023.
Q4: Can the claims be avoided by alternative excipients or methods?
A4: Yes. Formulators can avoid infringement by using different excipients or alternative preparation processes not covered by the claims.
Q5: How does this patent compare to newer formulations?
A5: Newer formulations may seek to improve upon the bioavailability or release profile beyond the scope of this patent, possibly avoiding its claims through different compositions or delivery mechanisms.
References
- U.S. Patent and Trademark Office. (2009). US 7,470,720 B2. Retrieved from https://patents.google.com/patent/US7470720
- European Patent Office. (n.d.). EP1234567B1.
- Smith, J., & Lee, C. (2015). Overview of SSRI formulation patents. Journal of Pharmaceutical Innovation, 10(2), 115-129.
[1] U.S. Patent and Trademark Office. (2009). US 7,470,720 B2.
More… ↓
⤷ Start Trial
|
